#Medicare

Medicare plans vary and can sometimes be difficult to decipher. Does your plan cover hepatitis C treatment?

The Trump administration had proposed changing which meds were covered, including HIV and cancer drugs.

The proposal rolls back nondiscrimination policies of the Affordable Care Act, notably for transgender people and women who had abortions.

Insurance companies can no longer implement harmful co-pay accumulator policies.

A look at the supply chain that results in very high costs for HIV and hepatitis C medications.

The patient advocacy coalition I Am Essential sent a letter to the HHS spelling out why the plan is dangerous.

Plans have increasingly instituted preauthorization requirements for the opioid medication-assisted treatment buprenorphine.

The drugs are set to come out in January 2019 with a list price of $24,000 for the most common dose for each.

The denial rate, which is higher for the privately insured than those with Medicaid or Medicare, is on the rise.

This is according to an analysis of hep C treatment rates at four large urban hospital systems.

Compared with their HIV-negative peers, HIV-positive individuals have higher rates of treatment for a host of health problems.

He’ll oversee the FDA, Medicare and Medicaid at a time when soaring drug prices remain a contentious political topic.

Older people with hepatitis C have some disadvantages compared with younger people.

He also told pharma leaders: “We have to get prices down. We have no choice.”

Tom Price now faces a Senate confirmation hearing.

Tom Price wants to dismantle Obamacare and Medicaid expansion, so why did the American Medical Association endorse him to lead HHS?